Akebia Therapeutics Inc. (AKBA) is priced at $2.21 after the most recent trading session. At the very opening of the session, the stock price was $2.29 and reached a high price of $2.3281, prior to closing the session it reached the value of $2.29. The stock touched a low price of $2.20.Recently in News on January 10, 2022, Akebia Therapeutics to Present at H.C. Wainwright Bioconnect Conference. Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that David Spellman, Chief Financial Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect Conference, which will take place virtually January 10-13, 2022. You can read further details here
Akebia Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.48 on 01/04/22, with the lowest value was $2.15 for the same time period, recorded on 01/10/22.
Akebia Therapeutics Inc. (AKBA) full year performance was -28.94%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Akebia Therapeutics Inc. shares are logging -57.00% during the 52-week period from high price, and 2.55% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $2.15 and $5.14.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2713416 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Akebia Therapeutics Inc. (AKBA) recorded performance in the market was -2.21%, having the revenues showcasing -24.83% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 394.51M, as it employees total of 380 workers.
The Analysts eye on Akebia Therapeutics Inc. (AKBA)
During the last month, 4 analysts gave the Akebia Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 1 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.73, with a change in the price was noted -0.30. In a similar fashion, Akebia Therapeutics Inc. posted a movement of -11.95% for the period of last 100 days, recording 2,472,610 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for AKBA is recording 0.71 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.71.
Technical rundown of Akebia Therapeutics Inc. (AKBA)
Raw Stochastic average of Akebia Therapeutics Inc. in the period of last 50 days is set at 4.60%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 13.25%. In the last 20 days, the company’s Stochastic %K was 24.28% and its Stochastic %D was recorded 20.01%.
Considering, the past performance of Akebia Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -2.21%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -33.43%, alongside a downfall of -28.94% for the period of the last 12 months. The shares increased approximately by -1.34% in the 7-day charts and went up by -13.33% in the period of the last 30 days. Common stock shares were lifted by -24.83% during last recorded quarter.